Objective: To evaluate the efficacy and safety of Laha acne topical solution combined with oral isotretinoin in the treatment of moderate acne vulgaris.
Subjects and methods: A two-phase study: a preclinical skin-irritation phase in 3 male New Zealand White rabbits, followed by a randomized controlled clinical trial in 70 patients with moderate acne vulgaris (35 per group). The study group received Laha acne solution twice daily plus oral isotretinoin (0.3–0.5 mg/kg/day); the control group received 4% erythromycin gel twice daily plus the same isotretinoin regimen, for 2 months.
Results: The solution caused only very slight erythema (irritation index 0.33, negligible). At month 2, excellent/good response rates were 25.7%/73.3% in the study group versus 2.9%/62.9% in the control group; no study-group patient had only moderate response versus 34.3% in controls (p < 0.05). Very-satisfied rates were 62.8% vs 31.5% (p < 0.05).
Conclusion: Topical Laha acne combined with oral isotretinoin was more effective than 4% erythromycin gel combined with isotretinoin, with good local tolerability and low irritation potential.